Syntaxin Ltd was established in 2005. The Company closed a $12M Series A financing in November 2005, led by Abingworth Management. In October 2007, Syntaxin secured a further $32M Series B financing led by SR One who were joined by JJDC and LSP with existing investors Abingworth. This provided broad investment and a wealth of corporate presence further strengthened by bringing Dr Eduard Holdener into the Syntaxin fold as an independent Non Executive Director.
Dr Holdener's wealth of big pharma experience completes the management team key hires of 2008 which saw appointments of Richard Jones as Chief Medical Officer, Nicki Thompson as Head of Discovery and Laurence Barker as Head of Business Development.
Prior to the formation of Syntaxin, the biotech research programmes were carried out at the Health Protection Agency (HPA) with grant support from the UK Department of Health and UK research councils, and sponsorship from Ipsen Ltd (formerly The Speywood Laboratory and Porton International Ltd).
The Company benefits from a strategic alliance with Allergan Inc, signed in 2000, for the discovery, development and commercialisation of proprietary engineered neurotoxin drugs for the treatment on pain disorders.